Treatment of allergy to heterologous monocomponent insulin with human semisynthetic insulin. Long-term study. 1988

B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
Karen Bruni Diabetes Center, Torino, Italy.

Eight type II (non-insulin-dependent) diabetic subjects (7 women, 1 man, aged 42-61 yr), initially treated with oral hypoglycemic agents and intermittently treated with conventional insulins, were identified as developing allergic reactions to porcine and mixed-species monocomponent insulin. Allergy was systemic (urticaria and nonthrombocytopenic purpura) and local delayed in two subjects and local immediate or biphasic in six subjects. Lipoatrophy was present in two subjects. After treatment with human semisynthetic insulin (Monotard HM and Actrapid HM), systemic allergy disappeared. Local allergy disappeared in five subjects and was reduced in three subjects. No lipoatrophy occurred in new injection areas. The clinical results were accompanied by a significant decrease in serum insulin-specific IgE after 6, 12, 18, 24, 30, and 36 mo. Insulin-specific IgG showed an evident decrease in five of eight patients, but the difference in mean values was not significant after 6, 18, 24, 30, and 36 mo. With one exception, intradermal skin tests were positive to human, bovine, and porcine insulin before and after human insulin treatment.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007330 Insulin Antibodies Antibodies specific to INSULIN. Antibodies, Insulin
D007428 Intradermal Tests Skin tests in which the sensitizer is injected. Passive Transfer Test,Prausnitz-Kustner Test,Intradermal Test,Passive Transfer Tests,Prausnitz Kustner Test,Test, Intradermal,Test, Passive Transfer,Test, Prausnitz-Kustner,Tests, Intradermal,Tests, Passive Transfer
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D005260 Female Females

Related Publications

B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
January 1986, Acta diabetologica latina,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
January 1984, Minerva endocrinologica,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
October 1983, Ugeskrift for laeger,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
November 1983, The Journal of the Association of Physicians of India,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
January 1974, The Netherlands journal of medicine,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
March 1979, Postgraduate medical journal,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
July 1985, Postgraduate medical journal,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
January 1984, Minerva endocrinologica,
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
September 1974, Polski tygodnik lekarski (Warsaw, Poland : 1960),
B Bruni, and P Barolo, and A Blatto, and M Carlini, and S G Ansaldi, and G Grassi
January 1977, Panminerva medica,
Copied contents to your clipboard!